Manufacturers of Xarelto are Being Investigated for their Marketing Strategies

February 5th, 2016

Drug companies Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, and Bayer Healthcare are being investigated by attorneys for their marketing strategies. For the blood-thinning drug Xarelto (rivaroxaban), these strategies were aimed at putting profits over safety. Even though Xarelto was said to surpass all other drugs of its kind in effectiveness, safety and ease of use, it turned out to be life-threatening for many users.

Xarelto, approved by the FDA in 2011, was prescribed largely to treat and prevent blood clots deep in the body and lungs, as well as atrial fibrillation, or an irregular heart rate. People taking this drug, however, have experienced deadly, irreversible internal bleeding. Xarelto is even more sinister than other blood-thinners because, whereas bleeds caused by Coumadin and warfarin can be reversed with Vitamin K, there is no way to halt the bleeding process caused by Xarelto. Compounding this, the drug companies claimed that Xarelto was easier to use because it did not involve the regular blood-monitoring tests required by other anticoagulants, even though such monitoring has been shown to prevent bleeds. Because they were not monitored by healthcare professionals, people taking this drug were at a far higher risk of suffering from uncontrollable internal bleeding, and were three times more likely to suffer death than people taking Coumadin or warfarin.

Because of the dangers of Xarelto, attorneys have filed lawsuits in a multidistrict litigation against the manufacturers of Xarelto. Multidistrict litigation, or MDL, is different than a class action suit because it treats every case and its injuries individually. The first trial in the MDL is scheduled for Fall 2016 in the Eastern District of Louisiana.

If you or a loved one have experienced the dangerous effects of Xarelto, we may be able to help. The attorneys at The Yost Legal Group are experienced professionals ready to investigate your claim with compassion and determination. For a free consultation, call us at 1-800-YOST-LAW.

Xarelto Update: First Federal MDL Trial Verdict

The first multi-district litigation (MDL) trial for the blood thinner medication Xarelto began just a few weeks ago. This drug is used to prevent blood clots in patients suffering from arrhythmic heart disorder. If not properly monitored, Xarelto increases the risk of severe internal bleeding. The legal team representing Xarelto victims argues that the manufacturer of the drug failed to properly warn the medical community of the danger of uncontrollable bleeding presented by Xarelto. Sadly,…

Read More »

Blood Thinner Medication Xarelto is Causing Severe Adverse Reactions baltimore defective drug lawyers, product liability attorneys in maryland, defective product law firm, medication error, side effects, Xarelto lawsuit

Earlier this year, The Yost Legal Group outlined the underlying factors of a Multidistrict Litigation (MDL) against the blood-thinner medication Xarelto. Since the announcement of this litigation at the end of 2014, a case that already appeared primed to become one of 2015’s largest mass tort drug cases has continued to grow as new patients harmed by this medication continue to come forward. The case against Xarelto and manufacturer Janssen Pharmaceuticals, a subsidiary of Johnson…

Read More »

Blood-Thinner Drug Xarelto Markets Convenience, But Puts Patients In Grave Danger defective drug lawyers baltimore, xarelto lawsuit, maryland product liability law firm, consumer safety

One of the first major drug torts of 2015 will center on the controversial anticoagulant medication known as Xarelto. Manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals as well as Bayer Corporation, Xarelto is part of a new breed of blood thinning drugs known as New Oral Anti-Coagulants (NOACs).   What’s new is that unlike the longstanding go-to drug Coumadin (Warfarin), this new generation of drugs promises the convenience of freedom from dietary restrictions and the…

Read More »